MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$259,462K
Proceeds from issuance of
common stock under the...
$462K
Proceeds from exercise of
stock options
$425K
Net cash provided by
(used in) investing...
$116,808K
Net cash provided by
financing activities
$887K
Canceled cashflow
$142,654K
Net (decrease)
increase in cash, cash...
-$10,817K
Canceled cashflow
$117,695K
Stockbased compensation
expense
$19,609K
Right-of-use assets,
operating leases
-$10,669K
Prepaid expenses and
other current assets
-$7,642K
Accrued expenses and
other current...
$4,742K
Depreciation expense
$4,096K
Collaboration receivable
-$2,503K
Other non-current
assets
-$214K
Purchases of marketable
securities
$141,613K
Purchases of property and
equipment
$1,041K
Net cash used in
operating activities
-$128,512K
Canceled cashflow
$49,475K
Net (loss) income
-$143,750K
Deferred revenue
-$19,825K
Operating lease
liabilities
-$8,275K
Net amortization of
premium (accretion of...
$3,671K
Accounts payable
-$1,799K
Income taxes payable
-$667K
Back
Back
Cash Flow
source: myfinsight.com
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)